AdvaMed response letter to OMB’s RFI on deregulation, highlighting support for regulatory reform that fosters medical innovation and improved patient care, dated May 12, 2025.
Emerging Policy Response Resources / Government & Legislative Affairs

OMB Request for Information on Deregulation

A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.

Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs

AdvaMed Testifies in U.S. Senate 

WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the Medtech Association, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs…